CytomX Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $246.00K, a 143.56% increase year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $101.00K, a 57.20% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $236.00K, a 18.90% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $291.00K, a 19.17% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $308.00K, a 23.76% decline from fiscal 2024.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $404.00K, a 24.49% decline from fiscal 2023.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $535.00K, a 2.55% decline from fiscal 2022.
- CytomX Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $549.00K, a 48.84% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $246.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $308.00K 10-K · filed 2026-03-16 | |
| 2025-06-30 | $101.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $404.00K 10-K · filed 2026-03-16 | |
| 2024-06-30 | $236.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $535.00K 10-K · filed 2025-03-06 | |
| 2023-06-30 | $291.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $549.00K 10-K · filed 2024-03-11 | |
| 2022-06-30 | $360.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $1.07M 10-K/A · filed 2023-03-27 | |
| 2021-06-30 | $518.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $729.00K 10-K/A · filed 2023-03-27 | |
| 2020-06-30 | $369.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $994.00K 10-K/A · filed 2023-03-27 | |
| 2019-06-30 | $665.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $872.00K 10-K · filed 2021-02-24 | |
| 2018-06-30 | $356.00K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $674.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | $287.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |